Business Context and Reporting Period
CareDx, Inc. is a precision-medicine company serving transplant patients through testing services, diagnostic products and digital solutions. This unaudited Form 10-Q covers the three months ended March 31, 2021; comparisons are with the first quarter of 2020 unless noted.
Key Financial Metrics
| Metric | Q1 2021 | Q1 2020 / prior date |
|---|---|---|
| Total revenue | $67.4 million | $38.4 million |
| Gross profit and margin | $45.8 million; approximately 68.0% | $26.0 million; approximately 67.7% |
| Operating expenses | $68.3 million | $44.1 million |
| Operating loss | $0.9 million | $5.8 million |
| Net loss | $0.7 million; $0.01 per share | $5.8 million; $0.14 per share |
| Cash used in operating activities | $33.6 million | $3.1 million |
| Cash, cash equivalents and marketable securities | $374.3 million at March 31, 2021 | $224.7 million at December 31, 2020 |
| Total liabilities / debt | $69.7 million / no debt outstanding | Total liabilities $90.8 million at December 31, 2020 |
Revenue comprised testing services of $59.3 million, products of $5.8 million, and digital and other of $2.3 million. Testing services represented 88% of revenue. Medicare accounted for approximately 60% of revenue, versus 53% a year earlier. The company reported an accumulated deficit of $353.2 million. Its current assets were $438.7 million and current liabilities were $45.7 million at quarter-end.
Material Changes Versus the Prior Period
- Revenue rose 76% year over year. Testing-services revenue increased 89%, principally reflecting more than 18,000 additional AlloSure Kidney, AlloMap Heart and AlloSure Heart patient results. Approximately 33,200 total AlloSure and AlloMap results were reported, including approximately 5,900 AlloSure Heart results.
- Product revenue grew 23%, primarily from NGS HLA typing products; digital and other revenue increased 4%, partly following the TransChart acquisition.
- Operating loss narrowed by $4.9 million, but operating expenses rose 55%, led by higher testing costs, research and development, sales and marketing, and general and administrative expenses. G&A included $2.1 million of legal fees.
- Operating cash outflow increased, substantially reflecting the $20.5 million repayment of the CMS advance and increases in accounts receivable, inventory and prepaid assets.
- A January–February public offering raised approximately $188.7 million net and issued approximately 2.21 million shares. Cash and securities increased; quarter-end common shares outstanding were 51.9 million, compared with 49.4 million at year-end 2020.
- The company acquired TransChart in January and BFS Molecular in March. TransChart added transplant EMR and referral software; the filing reports $2.3 million of goodwill and $2.0 million of intangible assets from that acquisition.
Outlook, Risks and Unusual Items
- Management said existing cash and expected operating and collaboration cash flows should fund anticipated cash requirements for at least 12 months. No specific revenue or earnings guidance was provided. The company expects continued losses and significant operating expenses.
- Management reported testing volumes at or above pre-pandemic levels through March 2021, with product sales also described as normal. COVID-19 could still disrupt suppliers, clinical studies, hospital activity and operations.
- Key business risks include dependence on payer coverage and collections, especially Medicare; competition; clinical and reimbursement uncertainty for current and future tests; supplier reliance; acquisition integration; and intellectual-property protection.
- CareDx disclosed Natera litigation, including false-advertising and patent claims, with trial scheduled to begin July 26, 2021. The company had recorded no liability and said it intended to defend the matters; outcomes and potential losses were uncertain.
- The filing also describes a former employee’s alleged unauthorized download of confidential and privileged information and related claims. CareDx said it was investigating and intended to pursue and defend the matters; no outcome was assured.
- CareDx had received approximately $4.8 million from the CARES Act Provider Relief Fund in 2020. It reported compliance efforts and recordkeeping, while noting uncertainty around program requirements and potential monitoring or audits.
- Unusual cash-flow item: the company repaid the full $20.5 million CMS advance in January 2021. The company had no outstanding debt at March 31, 2021.
Important Facts for Investors to Verify
- Whether test-result growth, payer coverage and collections translate into sustained revenue and improved operating profitability.
- How testing costs, RemoTraC costs and growing R&D and commercial expenses affect gross margin and cash burn.
- Medicare exposure, reimbursement rates and any developments in private-payer coverage or claims collection.
- Progress and outcomes of the Natera cases and former-employee matters, including potential costs or business impacts.
- Acquisition integration and commercial progress for TransChart and BFS Molecular.
- Use of offering proceeds, future financing needs and the effects of equity issuance and stock-based compensation on shareholders.
- Any changes to the stated 12-month liquidity outlook, CARES Act relief-fund compliance, or COVID-19-related clinical and supply-chain risks.